Difference between revisions of "Imipramine-bupropion"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = bupropion | | to = bupropion | ||
| stop = | | stop = | ||
| − | + | {{stopImipramine}} | |
| − | |||
| − | |||
| start = | | start = | ||
* '''Day 4:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of imipramine according to the scheme above. | * '''Day 4:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of imipramine according to the scheme above. | ||
| Line 12: | Line 10: | ||
* Bupropion is a strong inhibitor of CYP2D6, which metabolizes imipramine. | * Bupropion is a strong inhibitor of CYP2D6, which metabolizes imipramine. | ||
* {{RiskSeizureBupropionTCA}} | * {{RiskSeizureBupropionTCA}} | ||
| − | |||
}} | }} | ||
Latest revision as of 11:48, 4 November 2015
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from imipramine to bupropion.[1] [2]
Stop imipramine - Before day 1: gradually reduce dosage of imipramine to a maximum of 75 mg/ day, when this dosage is > 75 mg/day.
- Day 1-3: reduce dosage of imipramine to 50 mg/day.
- Day 4-7: reduce dosage of imipramine to 25 mg/day.
- Day 8: stop administration of imipramine.
Start bupropion- Day 4: simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of imipramine according to the scheme above.
- Day 8: stop administration of imipramine and continue administration of bupropion.
More information- Bupropion is a strong inhibitor of CYP2D6, which metabolizes imipramine.
- The concomitant use of bupropion and tricyclic antidepressants (TCAs) may potentiate the risk of seizures. These agents are all epileptogenic and may have additive effects on the seizure threshold.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
